Last reviewed · How we verify

modafinil (M1, M2, M4) — Competitive Intelligence Brief

modafinil (M1, M2, M4) (modafinil (M1, M2, M4)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Eugeroic (wakefulness-promoting agent). Area: Neurology / Sleep Medicine.

marketed Eugeroic (wakefulness-promoting agent) Dopamine transporter (DAT); norepinephrine transporter (NET); orexin system modulation Neurology / Sleep Medicine Small molecule Live · refreshed every 30 min

Target snapshot

modafinil (M1, M2, M4) (modafinil (M1, M2, M4)) — University of California, Los Angeles. Modafinil promotes wakefulness by increasing dopamine and norepinephrine activity in the brain, particularly in the hypothalamus and prefrontal cortex.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
modafinil (M1, M2, M4) TARGET modafinil (M1, M2, M4) University of California, Los Angeles marketed Eugeroic (wakefulness-promoting agent) Dopamine transporter (DAT); norepinephrine transporter (NET); orexin system modulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Eugeroic (wakefulness-promoting agent) class)

  1. University of California, Los Angeles · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). modafinil (M1, M2, M4) — Competitive Intelligence Brief. https://druglandscape.com/ci/modafinil-m1-m2-m4. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: